BR9712202A - Composto, processo para preparar o mesmo, composicão farmacêutica, processo para o tratamento de inflamacão neurogênica em um indivíduo em necessidade deste tratamento, e, uso do composto. - Google Patents

Composto, processo para preparar o mesmo, composicão farmacêutica, processo para o tratamento de inflamacão neurogênica em um indivíduo em necessidade deste tratamento, e, uso do composto.

Info

Publication number
BR9712202A
BR9712202A BR9712202-5A BR9712202A BR9712202A BR 9712202 A BR9712202 A BR 9712202A BR 9712202 A BR9712202 A BR 9712202A BR 9712202 A BR9712202 A BR 9712202A
Authority
BR
Brazil
Prior art keywords
treatment
compound
individual
pharmaceutical composition
need
Prior art date
Application number
BR9712202-5A
Other languages
English (en)
Inventor
Tine Krogh Jorgensen
Rolf Hohlweg
Peter Madsen
Knud Erik Andersen
Svend Treppendahl
Uffe Bang Olsen
Zdenek Polivka
Alexandra Silhankova
Karel Sindelar
Vladimir Valenta
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9712202A publication Critical patent/BR9712202A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, PROCESSO PARA PREPARAR O MESMO, COMPOSIçãO FARMACêUTICAS, PROCESSO PARA O TRATAMENTO DE INFLAMAçãO, NEUROGêNICA EM UM INDIVìDUO EM NECESSIDADE DESTE TRATAMENTO, E, USO DO COMPOSTO". A presente invenção refere-se a novos compostos N-substituídos azaheterocíclicos de fórmula geral (I), em que X, Y, Z, A, R^ 1^, R^ 2^, r e s são como definidos na parte detalhada da presente descrição ou sais dos mesmos, a processos para sua preparação, a composições contendo os mesmos, e ao seu uso para o tratamento clínico de condições dolorosas, hiperalgésicas e/ou inflamatórias em que as fibras C desempenham um papel patofisiológico por elicitação de dor neurogênica ou inflamação assim como seu uso para o tratamento de indicações provocadas por ou relacionadas com secreção e circulação de peptídeos antagonizando insulina.
BR9712202-5A 1996-10-04 1997-10-02 Composto, processo para preparar o mesmo, composicão farmacêutica, processo para o tratamento de inflamacão neurogênica em um indivíduo em necessidade deste tratamento, e, uso do composto. BR9712202A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK108996 1996-10-04
PCT/DK1997/000421 WO1998015546A1 (en) 1996-10-04 1997-10-02 N-substituted azaheterocyclic compounds

Publications (1)

Publication Number Publication Date
BR9712202A true BR9712202A (pt) 1999-08-31

Family

ID=8100875

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712202-5A BR9712202A (pt) 1996-10-04 1997-10-02 Composto, processo para preparar o mesmo, composicão farmacêutica, processo para o tratamento de inflamacão neurogênica em um indivíduo em necessidade deste tratamento, e, uso do composto.

Country Status (14)

Country Link
US (1) US6569849B1 (pt)
EP (1) EP0934306A1 (pt)
JP (1) JP2001501629A (pt)
KR (1) KR20000048909A (pt)
CN (1) CN1234797A (pt)
AU (1) AU741839B2 (pt)
BR (1) BR9712202A (pt)
CA (1) CA2267500A1 (pt)
CZ (1) CZ114199A3 (pt)
HU (1) HUP0000088A3 (pt)
IL (1) IL129122A0 (pt)
NO (1) NO991563L (pt)
PL (1) PL332593A1 (pt)
WO (1) WO1998015546A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2318088A1 (en) * 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
IL137266A0 (en) 1998-01-21 2001-07-24 Millennium Pharm Inc Heterocyclic chemokine receptor antagonists and pharmaceutical compositions containing the same
US6613905B1 (en) 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7271176B2 (en) 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
US20070066570A1 (en) * 2003-06-16 2007-03-22 Michael Solomon Methods for treating sleep disorders
AR047938A1 (es) * 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
SG172685A1 (en) 2006-06-28 2011-07-28 Amgen Inc Glycine transporter-1 inhibitors
US8034940B2 (en) 2006-08-09 2011-10-11 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
SE531698C2 (sv) 2007-07-12 2009-07-07 Respiratorius Ab Nya bronkdilaterande a,b-omättade amider
EP2944647A1 (en) 2007-07-26 2015-11-18 Cellay, Inc. Highly visible chromosome-specific probes and related methods
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
EP2385829B1 (en) 2009-01-09 2018-08-01 Board of Regents of the University of Texas System Pro-neurogenic compounds
DK2576830T3 (en) 2010-06-03 2014-12-08 Cellay Inc Methods for in situ detection of nucleotide sequences
EP2590647B1 (en) 2010-07-07 2017-11-08 Board of Regents of the University of Texas System Pro-neurogenic compounds
WO2013026455A1 (en) * 2011-08-24 2013-02-28 Aarhus Universitet Permanently positively charged antidepressants
DK2802671T3 (en) 2011-12-12 2018-11-05 Cellay Inc METHODS AND KITS FOR ROOM TEMPERATURE-IN SITU DETECTION OF A TARGET-NUCLEIC ACID IN A BIOLOGICAL SAMPLE
WO2014031986A1 (en) * 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
EP2914737B1 (en) 2012-10-31 2017-12-06 Cellay, Inc. Methods and kits for performing in situ hybridization
CA2929932A1 (en) 2013-11-07 2015-05-14 Cellay, Inc. Methods and kits for detecting a prostate carcinoma and predicting disease outcomes for prostate cancers
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
CN111171006B (zh) * 2020-01-29 2023-05-12 成都睿智化学研究有限公司 一种3-取代亚氨基二苄氨基类化合物的工艺方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3123610A (en) * 1964-03-03 Alkanoylpiperidinoalkyl
US3058979A (en) * 1957-05-13 1962-10-16 Smith Kline French Lab New perfluoroalkylphenothiazine derivatives
FR1212031A (fr) * 1957-10-21 1960-03-21 Rhone Poulenc Sa Dérivés de la phénothiazine substitués à l'azote par une chaîne basique comportant un hétérocycle et leur préparation
BE566958A (pt) * 1958-04-19
CH374682A (de) * 1959-08-28 1964-01-31 Geigy Ag J R Verfahren zur Herstellung von neuen N-heterocyclischen Verbindungen
FR1578748A (pt) * 1967-12-28 1969-08-22
DE1920170A1 (de) * 1968-04-20 1970-01-29 Egyt Gyogyszervegyeszeti Gyar Verfahren zur Herstellung von N-Heterocyclischen Verbindungen
NO127151B (pt) * 1969-03-28 1973-05-14 Ciba Geigy Ag
FR2005201B1 (pt) * 1969-05-20 1973-03-16 Auguil Ste Civile
GB1323659A (en) * 1971-04-10 1973-07-18 Yoshitomi Pharmaceutical Piperazine derivatives methods for their production and pharmaceuticl compositions containing them
US3828034A (en) * 1972-05-25 1974-08-06 Syntex Inc Tricyclic pharmacological agents,intermediates and methods of making
FR2186249A1 (en) * 1972-05-31 1974-01-11 Synthelabo Phenyl piperazinoalkyl (dihydro)dibenzazepines - antidepressants having low toxicity
US3965181A (en) * 1973-07-06 1976-06-22 Syntex (U.S.A.) Inc. Tricyclic pharmacological agents, intermediates and methods of making
GB1480593A (en) * 1973-11-30 1977-07-20 Kefalas As Xanthene and thioxanthene derivatives having pharmaceutical activity
DE3444837A1 (de) * 1984-12-08 1986-06-12 Basf Ag, 6700 Ludwigshafen 10,11-dihydro-5h-dibenzo(a,d)cycloheptadien- derivate, ihre herstellung und verwendung
MY113463A (en) * 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
US5716949A (en) * 1995-04-07 1998-02-10 Novo Nordisk A/S Heterocyclic compounds
DK0934312T3 (da) * 1996-10-04 2003-07-21 Novo Nordisk As 1,4-disubstituerede piperaziner
US6040318A (en) * 1997-06-25 2000-03-21 Novo Nordisk A/S Tricycle substituted with azaheterocyclic carboxylic acids

Also Published As

Publication number Publication date
HUP0000088A2 (hu) 2000-06-28
CN1234797A (zh) 1999-11-10
CZ114199A3 (cs) 1999-09-15
KR20000048909A (ko) 2000-07-25
HUP0000088A3 (en) 2000-09-28
WO1998015546A1 (en) 1998-04-16
EP0934306A1 (en) 1999-08-11
NO991563L (no) 1999-06-03
CA2267500A1 (en) 1998-04-16
US6569849B1 (en) 2003-05-27
AU4377197A (en) 1998-05-05
AU741839B2 (en) 2001-12-13
PL332593A1 (en) 1999-09-27
JP2001501629A (ja) 2001-02-06
IL129122A0 (en) 2000-02-17
NO991563D0 (no) 1999-03-30

Similar Documents

Publication Publication Date Title
BR9712202A (pt) Composto, processo para preparar o mesmo, composicão farmacêutica, processo para o tratamento de inflamacão neurogênica em um indivíduo em necessidade deste tratamento, e, uso do composto.
BR9806870A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, e, uso de um composto e processo para preparar o mesmo.
BR0214986A (pt) S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
BRPI0016395B8 (pt) derivados de adamantano
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9812944A (pt) Inibidores bicìclicos da cinase
BR9915967A (pt) Derivados de propanolamina substituìdos por arila, proceso para sua preparação, medicamentos contendo estes compostos e seu uso
BR0212455A (pt) Composto, formulação farmacêutica, combinação, uso de um composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, e, processo para preparar um composto
BR9910573A (pt) Compostos antipicornavirais, preparação e uso dos mesmos
BRPI0412527A (pt) composto, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica, e, processo para preparar um composto.
BR0113039A (pt) Composto ou um seu sal ou solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um indivìduo humano ou animal com uma condição antiinflamatória e/ou alérgica, e, processo para preparar um composto
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR9506452A (pt) Composto heterocíclico processo de preparação do composto heterocíclico composição farmacêutica composição farmacêutica adequada para o tratamento de inflamação neurogênica processo de tratamento de inflamação neurogênica em um individuo necessitado de tal tratamento e uso de um composto heterocíclico
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0315720A (pt) Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário
BR0210838A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com glicogênio sintase quinase-3, e de doenças, e medicação contraceptiva, e, processos para a preparação de um composto
BR0209271A (pt) Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
BR9811055A (pt) Composto , uso do mesmo, composição farmacêutica, e, processo para tratamento de doença ou condição médica mediada pelo fator xa
AR003440A1 (es) Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados.
BR0214553A (pt) Compostos, processo de preparação, em fase lìquida, dos compostos, e, composições farmacêuticas
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]